Cargando…
Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study
Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). T...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974205/ https://www.ncbi.nlm.nih.gov/pubmed/35386472 http://dx.doi.org/10.1002/dad2.12288 |
_version_ | 1784680215204593664 |
---|---|
author | Padilla, Concepcion Montal, Victor Walpert, Madeleine J. Hong, Young T. Fryer, Tim D. Coles, Jonathan P. Aigbirhio, Franklin I. Hartley, Sigan L. Cohen, Ann D. Tudorascu, Dana L Christian, Bradley T. Handen, Benjamin L. Klunk, William E. Holland, Anthony J. Zaman, Shahid H. |
author_facet | Padilla, Concepcion Montal, Victor Walpert, Madeleine J. Hong, Young T. Fryer, Tim D. Coles, Jonathan P. Aigbirhio, Franklin I. Hartley, Sigan L. Cohen, Ann D. Tudorascu, Dana L Christian, Bradley T. Handen, Benjamin L. Klunk, William E. Holland, Anthony J. Zaman, Shahid H. |
author_sort | Padilla, Concepcion |
collection | PubMed |
description | Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). The association between tau burden and cortical thickness was also examined at time point 3 (TP3). Results: Between TP1 and TP2 there was pronounced cortical thinning in temporo‐parietal cortices and cortical thickening in the frontal cortex. Baseline amyloid burden was strongly associated to cortical thinning progression, especially in the temporo‐parietal regions. At TP3, tau deposition negatively correlated with cortical atrophy in regions where tau usually accumulates at later Braak stages. Discussion: A higher amount of amyloid accumulation triggers a cascade of changes of disease‐causing processes that eventually lead to dementia. As expected, we found that regions where tau usually accumulates were those also displaying high levels of cortical atrophy. |
format | Online Article Text |
id | pubmed-8974205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89742052022-04-05 Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study Padilla, Concepcion Montal, Victor Walpert, Madeleine J. Hong, Young T. Fryer, Tim D. Coles, Jonathan P. Aigbirhio, Franklin I. Hartley, Sigan L. Cohen, Ann D. Tudorascu, Dana L Christian, Bradley T. Handen, Benjamin L. Klunk, William E. Holland, Anthony J. Zaman, Shahid H. Alzheimers Dement (Amst) Neuroimaging Introduction: The Down syndrome population has a high prevalence for dementia, often showing their first clinical symptoms in their 40s. Methods: In a longitudinal cohort, we investigate whether amyloid deposition at time point 1 (TP1) could predict cortical thickness change at time point 2 (TP2). The association between tau burden and cortical thickness was also examined at time point 3 (TP3). Results: Between TP1 and TP2 there was pronounced cortical thinning in temporo‐parietal cortices and cortical thickening in the frontal cortex. Baseline amyloid burden was strongly associated to cortical thinning progression, especially in the temporo‐parietal regions. At TP3, tau deposition negatively correlated with cortical atrophy in regions where tau usually accumulates at later Braak stages. Discussion: A higher amount of amyloid accumulation triggers a cascade of changes of disease‐causing processes that eventually lead to dementia. As expected, we found that regions where tau usually accumulates were those also displaying high levels of cortical atrophy. John Wiley and Sons Inc. 2022-04-01 /pmc/articles/PMC8974205/ /pubmed/35386472 http://dx.doi.org/10.1002/dad2.12288 Text en © 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Neuroimaging Padilla, Concepcion Montal, Victor Walpert, Madeleine J. Hong, Young T. Fryer, Tim D. Coles, Jonathan P. Aigbirhio, Franklin I. Hartley, Sigan L. Cohen, Ann D. Tudorascu, Dana L Christian, Bradley T. Handen, Benjamin L. Klunk, William E. Holland, Anthony J. Zaman, Shahid H. Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title_full | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title_fullStr | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title_full_unstemmed | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title_short | Cortical atrophy and amyloid and tau deposition in Down syndrome: A longitudinal study |
title_sort | cortical atrophy and amyloid and tau deposition in down syndrome: a longitudinal study |
topic | Neuroimaging |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8974205/ https://www.ncbi.nlm.nih.gov/pubmed/35386472 http://dx.doi.org/10.1002/dad2.12288 |
work_keys_str_mv | AT padillaconcepcion corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT montalvictor corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT walpertmadeleinej corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT hongyoungt corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT fryertimd corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT colesjonathanp corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT aigbirhiofranklini corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT hartleysiganl corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT cohenannd corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT tudorascudanal corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT christianbradleyt corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT handenbenjaminl corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT klunkwilliame corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT hollandanthonyj corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy AT zamanshahidh corticalatrophyandamyloidandtaudepositionindownsyndromealongitudinalstudy |